Based on 23 Wall Street analysts offering 12 month price targets for Boston Scientific in the last 3 months. The average price target is $61.45 with a high forecast of $66.00 and a low forecast of $56.00. The average price target represents a 14.65% change from the last price of $53.60.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Proxima_Nova_regular","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"37":"$37","52":"$52","67":"$67","44.5":"$44.5","59.5":"$59.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":66,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-17.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$66.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":61.45,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":-7.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$61.45</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":56,"label":{"className":"overflowvisible_force","align":"right","x":60,"y":2.5,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$56.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[37,44.5,52,59.5,67],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2022","6":"Mar<br/>2023","9":"Jun<br/>2023","12":"Sep<br/>2023","25":"Sep<br/>2024"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.62,54.57230769230769,55.52461538461538,56.47692307692307,57.42923076923077,58.38153846153846,59.33384615384615,60.286153846153844,61.238461538461536,62.190769230769234,63.14307692307692,64.09538461538462,65.0476923076923,{"y":66,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.62,54.22230769230769,54.824615384615385,55.426923076923075,56.02923076923077,56.63153846153846,57.23384615384615,57.83615384615385,58.43846153846154,59.04076923076923,59.643076923076926,60.245384615384616,60.84769230769231,{"y":61.45,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.62,53.80307692307692,53.98615384615385,54.169230769230765,54.35230769230769,54.535384615384615,54.71846153846154,54.90153846153846,55.08461538461538,55.26769230769231,55.45076923076923,55.63384615384615,55.816923076923075,{"y":56,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.9,"date":1663891200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.76,"date":1665100800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.59,"date":1667520000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.6,"date":1669939200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.33,"date":1672963200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.5,"date":1675382400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.82,"date":1677801600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.08,"date":1680825600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.54,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.82,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.29,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.72,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.62,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$66.00

Average Price Target$61.45

Lowest Price Target$56.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Stifel Nicolaus

xxxxxxxxxxxxx

Reiterated

2023-09-21

xxxxxxxxxxxxxxxxxx

Piper Sandler

xxxxxxxxxxxxx

Reiterated

2023-09-21

xxxxxxxxxxxxxxxxxx

UBS

xxxxxxxxxxxxx

Reiterated

2023-09-21

xxxxxxxxxxxxxxxxxx

Wolfe Research

xxxxxxxxxxxxx

Reiterated

2023-09-21

xxxxxxxxxxxxxxxxxx

Canaccord Genuity

xxxxxxxxxxxxx

Reiterated

2023-09-21

xxxxxxxxxxxxxxxxxx

Mizuho Securities

xxxxxxxxxxxxx

Assigned

2023-09-21

xxxxxxxxxxxxxxxxxx

Needham

xxxxxxxxxxxxx

Reiterated

2023-09-21

xxxxxxxxxxxxxxxxxx

Jefferies

xxxxxxxxxxxxx

Reiterated

2023-09-20

xxxxxxxxxxxxxxxxxx

Citi

xxxxxxxxxxxxx

Reiterated

2023-09-20

xxxxxxxxxxxxxxxxxx

J.P. Morgan

xxxxxxxxxxxxx

Reiterated

2023-09-20

Matt Miksic

Barclays

$60.00

Buy

11.94%

Upside

Reiterated

2023-09-20

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (NASDAQ: LIFE), Genfit SA (NASDAQ: GNFT) and Boston Scientific (NYSE: BSX)

David Rescott

Robert W. Baird

$63.00

Buy

17.54%

Upside

Reiterated

2023-09-20

Boston Scientific price target raised to $63 from $60 at BairdBoston Scientific price target raised to $63 from $60 at Baird

Shagun Singh Chadha

RBC Capital

$61.00

Buy

13.81%

Upside

Reiterated

2023-09-20

RBC on Boston Scientific (BSX) Long-Range Plan Released Earlier at Investor Day, we are encouragedRBC Capital analyst Shagun Singh reiterated an Outperform rating and $58.00 price target on Boston Scientific (NYSE: BSX).

Travis Steed

Bank of America Securities

$60.00

Buy

11.94%

Upside

Reiterated

2023-09-19

Analysts Have Conflicting Sentiments on These Healthcare Companies: Boston Scientific (NYSE: BSX), Apellis Pharmaceuticals (NASDAQ: APLS) and Healthequity (NASDAQ: HQY)

Marie Thibault

BTIG

$62.00

Buy

15.67%

Upside

Reiterated

2023-09-19

Analysts' Top Healthcare Picks: ContraFect (CFRX), Boston Scientific (BSX)

Best Analysts Covering Boston Scientific

Which Analyst Should I Follow If I Want to Buy BSX and Sell After:

1 Month

Rick WiseStifel Nicolaus

Success Rate

25/40 ratings generated profit

Average Return

+2.54%

reiterated a buy rating 4 days ago

Copying Rick Wise's trades and holding each position for 1 Month would result in 62.50% of your transactions generating a profit, with an average return of +2.54% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Joanne WuenschCiti

Success Rate

22/29 ratings generated profit

Average Return

+5.07%

reiterated a buy rating 5 days ago

Copying Joanne Wuensch's trades and holding each position for 3 Months would result in 75.86% of your transactions generating a profit, with an average return of +5.07% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Matthew TaylorJefferies

Success Rate

26/29 ratings generated profit

Average Return

+20.42%

reiterated a buy rating 5 days ago

Copying Matthew Taylor's trades and holding each position for 1 Year would result in 89.66% of your transactions generating a profit, with an average return of +20.42% per trade.

2 Years

Matthew TaylorJefferies

Success Rate

29/29 ratings generated profit

Average Return

+46.38%

reiterated a buy rating 5 days ago

Copying Matthew Taylor's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +46.38% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

BSX Financial Forecast

BSX Earnings Forecast

Next quarter’s earnings estimate for BSX is $0.48 with a range of $0.47 to $0.49. The previous quarter’s EPS was $0.53. BSX beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.63% of the time in the same period. In the last calendar year BSX has Underperformed its overall industry.

BSX Sales Forecast

Next quarter’s sales forecast for BSX is $3.48B with a range of $3.44B to $3.52B. The previous quarter’s sales results were $3.60B. BSX beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 44.61% of the time in the same period. In the last calendar year BSX has Outperformed its overall industry.

BSX Analyst Recommendation Trends

In the current month, BSX has received 16 Buy ratings 1 Hold ratings, and 0 Sell ratings. The BSX average analyst price target in the past 3 months is $61.45

BSX Stock Forecast FAQ

What is BSX’s average 12-month price target, according to analysts?

Based on analyst ratings, Boston Scientific’s 12-month average price target is $61.45.

What is BSX’s upside potential, based on the analysts’ average price target?

Boston Scientific has 14.65% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BSX a Buy, Sell or Hold?

Boston Scientific has a conensus rating of Strong Buy which is based on 20 buy ratings, 3 hold ratings and 0 sell ratings.

What is Boston Scientific’s price target?

The average price target for Boston Scientific is $61.45. This is based on 23 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $66.00 ,the lowest forecast is $56.00. The average price target represents 14.65% Increase from the current price of $53.6.

What do analysts say about Boston Scientific?

Boston Scientific’s analyst rating consensus is a Strong Buy. This is based on the ratings of 23 Wall Streets Analysts.

How can I buy shares of BSX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Boston Scientific (BSX) Stock Forecast & Price Target

BSX Analyst Ratings

BSX Stock 12 Months Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Boston Scientific

BSX Financial Forecast

BSX Earnings Forecast

BSX Sales Forecast

BSX Analyst Recommendation Trends

BSX Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts